Sodium polystyrene sulfonate


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Hyperkalaemia
Adult: Precise dose must be determined based on regular clinical and serum electrolyte monitoring. As suspension or powder for suspension: 15 g 1-4 times daily. Administer dose while patient is in an upright position.
Child: Precise dose must be determined based on regular clinical and serum electrolyte monitoring. Employ lower doses using, as a guide, a rate of 1 mEq of K/g of resin as the basis for calculation. For acute cases: Initially, 1 g/kg daily in divided doses. Maintenance: 0.5 g/kg daily in divided doses.

Rectal
Hyperkalaemia
Adult: Precise dose must be determined based on regular clinical and serum electrolyte monitoring. For patients with upper gastrointestinal tract problems or those who are vomiting: As enema: As suspension or powder for suspension: 30-50 g daily or given 6 hourly. Retain the enema for as long as possible or for at least 9 hours, then irrigate the colon using a non-sodium containing solution to remove the resin. If both oral and rectal routes are used initially, it may be unnecessary to continue rectal use once the oral resin has reached the rectum. Dosage recommendations may vary among countries and individual products (refer to detailed product guideline).
Child: Use a dose at least as great as that which would have been given via oral route and dilute in the same ratio as described for adults. Retain the enema for as long as possible or for at least 9 hours, then irrigate the colon using a non-sodium containing solution to remove the resin. If both oral and rectal routes are used initially, it may be unnecessary to continue rectal use once the oral resin has reached the rectum. Refer to detailed product guideline for further dosing information.
Hướng dẫn pha thuốc
Powder for suspension: Oral: Reconstitute in a small amount of water or syrup (in a ratio of 3-4 mL per g of resin); do not mix with fruit juices which contain K. Rectal: Reconstitute 1 g of resin with 5 mL of water or 10% dextrose solution; usually 30-50 g resin in 100 mL or 150 mL water or 10% dextrose solution (in adults).
Chống chỉ định
Hypokalaemia or serum K levels <5 mmol/L, obstructive bowel disease. Oral administration in neonates; neonates with reduced gut motility (postoperatively or drug-induced).
Thận trọng
Patient with severe CHF, severe hypertension, oedema, hypovolaemia. Consider other definitive measures (e.g. dialysis) or concomitant therapy (e.g. IV Na bicarbonate) in cases where rapid correction of severe hyperkalaemia is required. Avoid use in patients at risk of developing constipation or impaction (e.g. history of impaction, chronic constipation, ischaemic colitis, vascular intestinal atherosclerosis, previous bowel resection). Renal impairment. Neonates including premature or low birthweight infants (rectal); children. Pregnancy and lactation. Concomitant use with sorbitol is not recommended.
Tác dụng không mong muốn
Significant: Electrolyte disturbances (e.g. severe hypokalaemia, hypocalcaemia, hypomagnesaemia, Na retention); faecal impaction (after rectal administration, mainly in children); constipation, serious gastrointestinal adverse events (e.g. bleeding, ischaemic colitis, perforation). Rarely, acute bronchitis and bronchopneumonia (following inhalation of resin particles).
Gastrointestinal disorders: Nausea, vomiting, occasional diarrhoea, gastric irritation; bezoar formation (after oral administration).
Metabolism and nutrition disorders: Anorexia.
Potentially Fatal: Rarely, intestinal necrosis.
Chỉ số theo dõi
Monitor serum electrolytes (e.g. K, Na, Ca, Mg); ECG (in selected patients); bowel function. Monitor for signs and symptoms of fluid overload in patients sensitive to Na intake (e.g. CHF, hypertension, oedema).
Quá liều
Symptoms: Hypokalaemia (e.g. muscle weakness, irritability, delayed thought process, confusion, hyporeflexia and eventual paralysis and/or apnoea), cardiac arrythmia, hypocalcaemic tetany. Management: Correct serum electrolytes (Ca, K, Mg). Use laxatives or enemas to remove the resin from the alimentary tract.
Tương tác
May decrease absorption and efficacy of other oral medications; administer 3 hours before or after other oral drugs (consider 6-hour interval in patients with gastroparesis). May cause systemic alkalosis when given with non-absorbable cation-donating antacids and laxatives (e.g. Mg hydroxide or Al carbonate); avoid concomitant use with Mg-containing laxatives. May increase the risk of intestinal obstruction with Al hydroxide. May enhance the adverse or toxic effects of digoxin. May decrease the serum concentration of lithium and levothyroxine.
Potentially Fatal: Increased risk of intestinal necrosis and other serious gastrointestinal adverse effects with sorbitol.
Tương tác với thức ăn
Avoid mixing in orange juice or in any fruit juice containing K.
Tác dụng
Description: Sodium polystyrene sulfonate is a cation-exchange resin that reduces K levels by exchanging Na for K ions in the intestine, particularly the large intestine, before it passes from the body. The exchange capacity for each g of resin is approx 1 mEq of K in vivo, and approx 3.1 mEq of K in vitro.
Onset: Hours to days.
Pharmacokinetics:
Absorption: Not absorbed from the gastrointestinal tract.
Excretion: Via faeces (mainly as K polystyrene sulfonate).
Bảo quản
Store between 15-30°C. Freshly prepared suspensions should be used within 24 hours.
Phân loại MIMS
Thuốc giải độc & khử độc
Phân loại ATC
V03AE01 - polystyrene sulfonate ; Belongs to the class of drugs used in the treatment of hyperkalemia and hyperphosphatemia.
Tài liệu tham khảo
Anon. Sodium Polystyrene Sulfonate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 22/07/2021.

Buckingham R (ed). Sodium Polystyrene Sulfonate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/07/2021.

Joint Formulary Committee. Sodium Polystyrene Sulfonate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/07/2021.

Resonium A (Aventis Pharma Limited). MHRA. https://products.mhra.gov.uk. Accessed 22/07/2021.

Sanofi-Aventis New Zealand Limited. Resonium A Powder 3.1 mEq/g data sheet 28 March 2018. Medsafe. http://www.medsafe.govt.nz. Accessed 20/08/2021.

Sodium Polystyrene Sulfonate Powder for Suspension (Atlantic Biologicals Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 22/07/2021.

Sodium Polystyrene Sulfonate Suspension (CMP Pharma, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 22/07/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Sodium polystyrene sulfonate từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Kayexalate
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in